Efficacy and safety of remimazolam in patients with obstructive jaundice

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400091200

Enrollment

Unknown

Registered

2024-10-23

Start date

2024-11-01

Completion date

Unknown

Last updated

2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obstructive jaundice

Interventions

patients without obstructive jaundice undergoing endoscopic ERCP:None

Patients with obstructive jaundice undergoing endoscopic ERCP:None

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Jaundiced and non-jaundiced patients undergoing ERCP surgery (1) The age range is 18-75 years; (2) ASA grade I-IIl; (3) No disturbance of consciousnesss,able to cooperate with medical instructions; (4) The patient gave informed consent and signed the written informed consent

Exclusion criteria

Exclusion criteria: (1) Those allergic to remimazolam; (2) Patients with hepatic encephalopathy, neurological or mental illness; (3) Patients with respiratory dysfunction, sleep apnea; (4) Patients with alcoholism, or chronic use of painkillers, sedatives, and psychotropic drugs

Design outcomes

Primary

Measure	Time frame
Ramsay score;Time of awakening;	—

Secondary

Measure	Time frame
Blood pressure;Oxygen saturation;Heart rate;Pulse;Satisfaction to sedation by endoscopist;The willingness to return for a second endoscope examination;Postoperative extra sleep;Postoperative adverse reaction;	—

Countries

China

Contacts

Public ContactLi Yiqing

Li Huili Hospital, Ningbo Medical Center

liyiqing1123@163.com+86 139 5749 0237

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026